Haleon plc (HLN)
Haleon plc operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Weybridge, GB. The stock last traded at $9.81, down 1.21% on the session, giving a market capitalisation of $43.22B. On trailing twelve-month figures it carries a trailing P/E of 19.39, a net margin of 15.1%. Its beta of 0.24 implies it has historically moved less than the broad market.
Haleon plc is a significant global entity in the consumer healthcare sector, engaging in the entire process from scientific research and development to the production and worldwide distribution of various wellness goods. The company's reach extends across North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific region. Its diverse product portfolio encompasses therapeutic solutions for oral care, pain management, respiratory well-being, and digestive health, alongside a comprehensive range of vitamins, minerals, and other dietary supplements. Noteworthy brands within its collection include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. Established in 2021, the company was initially known as DRVW 2022 plc before officially changing its name to Haleon plc in February 2022. It is headquartered in Brentford, United Kingdom.
Haleon plc is most often compared with the following Healthcare names: